Homocysteine-lowering therapy for preventing atherothrombotic events: its role in high risk population

Area of Science:

• Cardiovascular Science
• Metabolic Disease Research
• Clinical Nutrition

Background:

• Elevated homocysteine levels are recognized as a risk factor for atherothrombotic events.
• Previous research suggested a potential benefit of homocysteine-lowering vitamins in cardiovascular disease prevention.

Discussion:

• Recent clinical trials have not provided sufficient evidence to recommend homocysteine-lowering vitamins for improving cardiovascular outcomes in high-risk populations.
• The association between homocysteine and cardiovascular risk does not automatically translate to a proven benefit from lowering homocysteine levels.

Key Insights:

• Current evidence is insufficient to initiate homocysteine-lowering vitamin therapy for cardiovascular risk reduction.
• The clinical utility of homocysteine-lowering interventions remains uncertain despite the established association with atherothrombosis.

Outlook:

• Large-scale, adequately powered clinical trials are necessary to definitively clarify the role of homocysteine-lowering vitamins in cardiovascular outcomes.
• Future research should focus on specific high-risk populations and robust trial designs to ascertain the efficacy of these interventions.